LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of February 14, 2025, LXRX stock price climbed to $0.78 with 2,493,368 million shares trading.

LXRX has a beta of 2.67, meaning it tends to be more sensitive to market movements. LXRX has a correlation of 0.10 to the broad based SPY ETF.

LXRX has a market cap of $283.74 million. This is considered a Small Cap stock.

Last quarter Lexicon Pharmaceuticals reported $2 million in Revenue and -$.18 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.02.

In the last 3 years, LXRX traded as high as $3.79 and as low as $.62.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, IWM, VXF, SCHA, VHT.

LXRX has underperformed the market in the last year with a price return of -73.2% while the SPY ETF gained +24.8%. LXRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -28.0% and -4.2%, respectively, while the SPY returned +2.4% and +0.8%, respectively.

LXRX support price is $.69 and resistance is $.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.